RenovoRx, Inc. (RNXT) DCF Valuation
- ✓ Entièrement Modifiable: Adapté À Vos Besoins Dans Excel Ou Sheets
- ✓ Conception Professionnelle: Modèles Fiables Et Conformes Aux Normes Du Secteur
- ✓ Pré-Construits Pour Une Utilisation Rapide Et Efficace
- ✓ Aucune Expertise N'Est Requise; Facile À Suivre
RenovoRx, Inc. (RNXT) Bundle
Evaluate RenovoRx, Inc. (RNXT)'s financial outlook like an expert! This (RNXT) DCF Calculator provides pre-filled financial data along with the flexibility to modify revenue growth, WACC, margins, and other essential assumptions to align with your projections.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Revenue Growth, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITDA | .0 | .0 | -5.7 | -9.9 | -11.4 | .0 | .0 | .0 | .0 | .0 |
| EBITDA, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Depreciation | 3.9 | 3.2 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Depreciation, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| EBIT | -3.9 | -3.2 | -5.7 | -10.0 | -11.4 | .0 | .0 | .0 | .0 | .0 |
| EBIT, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Total Cash | 2.1 | 1.8 | 15.2 | 6.4 | 1.2 | .0 | .0 | .0 | .0 | .0 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Inventories | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Inventories, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Accounts Payable | .5 | .2 | .5 | .5 | .6 | .0 | .0 | .0 | .0 | .0 |
| Accounts Payable, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Capital Expenditure | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Capital Expenditure, % | 100 | 100 | 100 | 100 | 100 | 0 | 0 | 0 | 0 | 0 |
| Tax Rate, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITAT | -3.8 | -3.7 | -6.4 | -9.8 | -11.4 | .0 | .0 | .0 | .0 | .0 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | .6 | -.9 | -6.0 | -9.8 | -11.4 | -.6 | .0 | .0 | .0 | .0 |
| WACC, % | 9.14 | 9.14 | 9.14 | 9.14 | 9.14 | 9.14 | 9.14 | 9.14 | 9.14 | 9.14 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -.5 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | 0 | |||||||||
| Terminal Value | 0 | |||||||||
| Present Terminal Value | 0 | |||||||||
| Enterprise Value | -1 | |||||||||
| Net Debt | -1 | |||||||||
| Equity Value | 1 | |||||||||
| Diluted Shares Outstanding, MM | 10 | |||||||||
| Equity Value Per Share | 0.06 |
What You Will Get
- Comprehensive RNXT Financials: Access historical and projected data for precise valuation.
- Customizable Inputs: Adjust WACC, tax rates, revenue growth, and capital expenditures as needed.
- Real-Time Calculations: Intrinsic value and NPV are computed automatically.
- Scenario Analysis: Explore various scenarios to assess RenovoRx's future performance.
- User-Friendly Design: Designed for industry professionals while remaining approachable for newcomers.
Key Features
- Customizable Treatment Parameters: Adjust essential inputs like treatment efficacy, patient demographics, and operational costs.
- Instant Efficacy Analysis: Provides real-time assessments of treatment outcomes and cost-effectiveness.
- High-Precision Results: Utilizes RenovoRx’s proprietary data for accurate treatment valuations.
- Streamlined Scenario Testing: Easily evaluate various treatment scenarios and analyze their impacts.
- Efficiency Booster: Avoid the hassle of developing intricate treatment models from the ground up.
How It Works
- Step 1: Download the Excel file.
- Step 2: Review pre-entered RenovoRx, Inc. (RNXT) data (historical and projected).
- Step 3: Adjust key assumptions (yellow cells) based on your analysis.
- Step 4: View automatic recalculations for RenovoRx, Inc. (RNXT)’s intrinsic value.
- Step 5: Use the outputs for investment decisions or reporting.
Why Choose RenovoRx, Inc. (RNXT) Calculator?
- Comprehensive Tool: Offers DCF, WACC, and financial ratio analyses all in one platform.
- Customizable Inputs: Modify the highlighted cells to explore different financial scenarios.
- Detailed Insights: Automatically computes RenovoRx’s intrinsic value and Net Present Value.
- Preloaded Data: Access to historical and projected data for reliable analysis.
- Professional Quality: Perfect for financial analysts, investors, and business consultants in the healthcare sector.
Who Should Use This Product?
- Investors: Accurately assess RenovoRx’s fair value before making investment decisions.
- CFOs: Utilize a professional-grade DCF model for financial reporting and analysis specific to RenovoRx (RNXT).
- Consultants: Efficiently customize the template for valuation reports tailored to RenovoRx (RNXT) clients.
- Entrepreneurs: Acquire insights into financial modeling practices employed by leading biotech firms.
- Educators: Implement it as a teaching resource to illustrate valuation methodologies relevant to the biotech sector.
What the Template Contains
- Preloaded RNXT Data: Historical and projected financial data, including revenue, EBIT, and capital expenditures.
- DCF and WACC Models: Professional-grade sheets for calculating intrinsic value and Weighted Average Cost of Capital.
- Editable Inputs: Yellow-highlighted cells for adjusting revenue growth, tax rates, and discount rates.
- Financial Statements: Comprehensive annual and quarterly financials for deeper analysis.
- Key Ratios: Profitability, leverage, and efficiency ratios to evaluate performance.
- Dashboard and Charts: Visual summaries of valuation outcomes and assumptions.